LIVING HOPE BREAST CANCER PATIENTS STADIUM AT BEGINNING OF HER-2 Positive Trastuzumab Adjuvant Therapy THAT GET IN GENERAL HOSPITAL CENTER DR. Sardjito
ABSTRACT: Background. Trastuzumab is the standard treatment of HER2-positive early breast cancer. It has been given since 2007 in Dr Sardjito Hospital. However, its efficacy and safety have not been assessed. This study evaluates the efficacy and safety of trastuzumab therapy. Objectives. The primary endpoint of this study was to assess overall survival (OS) and disease free survival (DFS) of HER2-positive early breast cancer in Dr Sardjito Hospital. The secondary endpoint was to assess the cardiotoxicity of trastuzumab therapy. Methods. Data of HER2-positive early breast cancer receiving adjuvant trastuzumab therapy between January 2007 and Desember 2014 were retrospectively reviewed. Overall survival and DFS were analyzed using Kaplan-Meier method. The log rank test was performed to analyze the difference between survival curves. Results. Ninety-five subjects were followed with a median duration of 26 months. The estimated OS and DFS rates at 1 year were 96,8% and 93,6% respectively among patients receiving trastuzumab. Subjects who started chemotherapy earlier (within less than 21 days from surgery) had better OS and DFS than the subject who received late chemotherapy (1-year OS was 100% vs 96% and 1-year DFS was 100% vs 92 %). Subjects treated with trastuzumab with longer duration (within more than 1 year) had better OS and DFS than the subjects whose duration was shorter (1-year OS was 100% vs 96.2% and 1-year DFS was 100% vs 92,3%). No significant differences in OS and DFS were found based on hormonal receptor status and route of administration. Cardiac toxicity incidence was 11,6% (11/95) in patients receiving trastuzumab, which is similar with other studies. Conclusion. The survival rate of subjects with early HER-2 positive breast cancer treated with adjuvant trastuzumab in Dr Sardjito Hospital are 96,8% for 1-year OS and 93,6% for 1-year DFS. Cardiotoxicity incidence is 11,6% in Patients receiving adjuvant trastuzumab therapy.
